An observational study in Hepatic Hemangioma, sponsored by Beijing Tiantan Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Beijing Tiantan Hospital · Observational
The goal of this observational study is to learn about the efficacy-safety profiles of combined hepatic arterial embolization (TAE) and laparoscopic radiofrequency ablation (RFA) in patients with hepatic hemangioma who receive sequential TAE-RFA treatment. The main question it aims to answer is: Does the time interval between TAE and subsequent RFA influence therapeutic efficacy and safety in patients with hepatic hemangioma receiving sequential TAE-RFA therapy? Participants already undergoing TAE followed by RFA as part of their regular clinical management for hepatic hemangioma will undergo scheduled laboratory tests and contrast-enhanced abdominal CT examinations over a 12-month follow-up period.
68 studies on the registry are indexed under Hemangioma; 11 are open to participants now.
This study's planned enrollment of 80 is above the median of 71 across 24 observational studies indexed under Hemangioma.
Browse Hemangioma studies →Beijing Tiantan Hospital is the lead sponsor of 489 studies on the registry; 293 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients aged 18-80 years with hepatic hemangioma >5 cm, eligible for transarterial embolization (TAE), and with acceptable liver function reserve. Patients with contrast allergy or anesthesia contraindications are excluded. Enrolled participants are stratified into two cohorts according to the time interval between TAE and subsequent laparoscopic radiofrequency ablation (RFA): short-interval group (10-14 days after TAE) and long-interval group (2-3 months after TAE).
Inclusion Criteria: Age 18-80 years; definite HH diagnosis via abdominal imaging with diameter > 5 cm; identifiable feeding artery suitable for embolization; preserved hepatic reserve without severe pre-existing liver disease; no contrast media allergy; no surgical anesthesia ; subjects understand procedural risks and are willing for study participation.
- Exclusion Criteria: Uncertain HH diagnosis where other solid hepatic lesions cannot be excluded; hepatic insufficiency, liver cirrhosis, ascites, hepatic encephalopathy; concurrent active anti malignant tumor therapy for hepatic or extra hepatic neoplasms; contrast media allergy or severe cardiopulmonary cerebrovascular diseases precluding procedural tolerance; pregnant or lactating women, patients with pregnancy planning requirements; refusal of study participation after adequate information disclosure.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RFA is performed at 10-14 days after TAE
Procedure: transcatheter arterial embolization (TAE) · Procedure: radiofrequency ablation (RFA)
RFA is performed at 2-3 months after TAE
Procedure: transcatheter arterial embolization (TAE) · Procedure: radiofrequency ablation (RFA)
Right femoral artery access; embolic agents: gelatin sponge particles combined with lipiodol; procedural endpoint: cessation of lipiodol inflow into hemangioma lesion
Laparoscopic radiofrequency ablation to facilitate intra operative bleeding surveillance and ablation zone assessment. Hepatic inflow occlusion will be performed for lesions \>10 cm
Tumour volume reduction rate
Time frame: 6 month and 12 month post RFA
Peri-procedural complication incidence
Time frame: day 1 post TAE and day 1 / day 4 post RFA
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.